Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

The effect of thalidomide on visceral fat pad mass and triglyceride concentration of the skeletal muscles in rats

  • Kim, Ki-Hoon (Department of Leisure & Sports, Kyungpook National University) ;
  • Choi, Chang-Bon (School of Biotechnology, Yeungnam University) ;
  • Kim, Jong-Yeon (Department of Obesity-Diabetes Advanced Research Center, Yeungnam University)
  • Received : 2018.11.20
  • Accepted : 2018.12.06
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Body fats, especially both of abdominal fat pad mass and skeletal muscle fat content, are inversely related to insulin action. Therefore, methods for decreasing visceral fat mass and muscle triglyceride content may be helpful for the prevention of insulin resistance. Methods: Thalidomide, used for its anti-angiogenic and anti-inflammatory properties, was administered to rats for 4 weeks. A 10% solution of thalidomide in dimethyl sulfoxide was injected daily into the peritoneal cavity as much as 100 mg/kg of body weight. Results: The total visceral fat pad mass in the thalidomide-treated group was 11% lower than in the control group. The size of adipocytes of the epididymal fat pad mass in the thalidomide-treated group was smaller than in the control group. The intraperitoneal thalidomide treatment increased triglyceride concentrations by 16% in the red muscle, but not in the white muscle. Conclusion: The results suggested that intraperitoneal thalidomide treatment inhibited abdominal fat accumulation, and that the free fatty acids in the blood were preferentially accumulated in the red muscle rather than in the white muscle.

Keywords

References

  1. Kim JY, Nolte LA, Hansen PA, Han DH, Ferguson K, Thompson PA, et al. High-fat diet-induced muscle insulin resistance: relationship to visceral fat mass. Am J Physiol Regul Integr Comp Physiol 2000;279:R2057-65. https://doi.org/10.1152/ajpregu.2000.279.6.R2057
  2. Kim JY, Nolte LA, Hansen PA, Han DH, Kawanaka K, Holloszy JO. Insulin resistance of muscle glucose transport in male and female rats fed a high-sucrose diet. Am J Physiol 1999;276:R665-72.
  3. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999;48:1113-9. https://doi.org/10.2337/diabetes.48.5.1113
  4. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999;42:113-6. https://doi.org/10.1007/s001250051123
  5. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5. https://doi.org/10.1073/pnas.91.9.4082
  6. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005;106:125-34. https://doi.org/10.1182/blood-2004-09-3679
  7. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509.
  8. Frayn KN, Maycock PF. Skeletal muscle triacylglycerol in the rat: methods for sampling and measurement, and studies of biological variability. J Lipid Res 1980;21:139-44.
  9. Denton RM, Randle PJ. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion. Biochem J 1967;104:416-22 https://doi.org/10.1042/bj1040416
  10. Teo SK, Evans MG, Brockman MJ, Ehrhart J, Morgan JM, Stirling DI, et al. Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs. Toxicol Sci 2001;59:160-8. https://doi.org/10.1093/toxsci/59.1.160
  11. Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman VH, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13:1047-54. https://doi.org/10.1089/aid.1997.13.1047
  12. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002;99:10730-5. https://doi.org/10.1073/pnas.162349799
  13. Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, et al. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res 2003;93:e88-97.
  14. Nakamitsu PZ, Compri CM, de Fraia Pinto L, Gotardo EM, de Oliveira CC, Ribeiro ML, et al. Thalidomide controls adipose tissue inflammation associated with high-fat diet-induced obesity in mice. Endocr Metab Immune Disord Drug Targets 2015;15:151-8. https://doi.org/10.2174/1871530314666141128115225
  15. Kelley DE, Goodpaster BH, Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr 2002;22:325-46. https://doi.org/10.1146/annurev.nutr.22.010402.102912
  16. Hua N, Takahashi H, Yee GM, Kitajima Y, Katagiri S, Kojima M, et al. Influence of muscle fiber type composition on early fat accumulation under high-fat diet challenge. PLoS One 2017;12:e0182430. https://doi.org/10.1371/journal.pone.0182430
  17. Korach-Andre M, Gao J, Gounarides JS, Deacon R, Islam A, Laurent D. Relationship between visceral adiposity and intramyocellular lipid content in two rat models of insulin resistance. Am J Physiol Endocrinol Metab 2005;288:E106-16. https://doi.org/10.1152/ajpendo.00089.2004
  18. Hall JE. Guyton and Hall textbook of medical physiology. 13th ed. Philadelphia: Elsevier; 2016. p. 84.